Background. Recent studies have shown that some vaccines have beneficial effects that cannot be explained solely by the prevention of their respective targeted disease(s).
Childhood vaccinations have been one of the greatest public health achievements in the past century. Vaccines are rigorously evaluated prelicensure in clinical trials, establishing their safety and efficacy against their targeted diseases. However, recent studies have identified possible nonspecific vaccine effects in children beyond their targeted infections. Studies in West Africa found that the measles vaccine [1] and bacillus Calmette-Guérin vaccine [2] had beneficial, nonspecific effects that could not be explained solely by the prevention of measles and tuberculosis, respectively. In the first study in a high-income country (Denmark), Sørup et al found that receipt of the live measles-mumps-rubella (MMR) vaccine as the most recent vaccine was associated with a lower rate of admissions for infections compared with receipt of diphtheria-tetanus-acellular pertussis-inactivated polio virus-Haemophilus influenzae type b (DTaP-IPV-Hib) as the most recent inactivated vaccine by age 15 months [3] .
In the United States, the current childhood vaccination schedule recommends routine vaccination with live vaccines at age intervals that are similar to those for recommended doses of inactivated vaccines. For example, the recommended age for 2 of the live vaccines, MMR and varicella (12 to 15 months), overlaps the recommended ages for doses of the following inactivated vaccines: H. influenzae type b (Hib; 12 to 15 months), pneumococcal conjugate vaccine (PCV) (12 to 15 months), hepatitis B vaccine (HBV; 6 to 18 months), inactivated poliovirus vaccine (IPV; 6 to 18 months), hepatitis A (HAV; 12 to 23 months), and DTaP (15 to 18 months).
We assessed hospital admissions due to nontargeted infections (NTI) in a US population of children according to the type of the last vaccine received. We attempted to replicate the study by Sørup and colleagues [3] using similar methods to the extent possible. We also conducted secondary analyses to assess different types of NTIs.
individual data from commercial health insurance claims and has a wide geographical representation [4, 5] . Because no birthdate is available, we used as a proxy the diagnosis-related group codes 789 through 795 (Centers for Medicare & Medicaid Services; https://www.findacode.com/code-set.php?-set=DRG&mdc=15) for newborn hospitalization to identify patients and included individuals who were enrolled in their insurance plan continuously from within a month of the birth hospitalization through 15 months. We defined birthdate as the date of admission for the newborn hospitalization. We evaluated children who had received at least 3 doses of DTaP prior to age 16 months to limit the possibility of bias attributable to factors related to undervaccination [6] . We excluded children enrolled in capitated insurance plans because of the lack of incentive among their providers to report individual claims for immunization services. We also excluded children who were immunosuppressed or had other contraindications for receiving vaccines. (See the Supplementary Table 5 for International Classification of Diseases, ninth revision [ICD-9] codes.) Also, because influenza vaccination was low or nonexistent in Denmark [7] during the period of the Sørup study [3] , we excluded children who had ever received an influenza vaccination (ie, any time up until 25 months).
Vaccine Status Information
Types of vaccines received were identified using individual Current Procedural Terminology (CPT) codes. Inactivated vaccines included DTaP, Hib, IPV, inactivated influenza vaccine (IIV), PCV, HAV, and HBV. Live vaccines included measles-mumps-rubella-varicella (MMRV), varicella, rotavirus, and live attenuated influenza vaccine (LAIV; licensed for ages 2-49 years). Because certain vaccines (eg, inactivated: HAV and DTaP) may still be administered between the ages of 16 and 24 months, vaccination status was treated as a time-dependent exposure. The children's vaccination status was defined as follows: inactivated and live vaccines received on the same day; live vaccines only; and inactivated vaccines only. The first occurrence of vaccination status was the last vaccine received prior to 16 months. If a vaccine was received between 16 months and 24 months, the vaccination status changed accordingly on the date of vaccination.
Outcomes
For comparability, we assessed the same infectious conditions/ outcomes evaluated by Sørup and colleagues [3] (Supplementary  Table 5 ). We evaluated up to 15 secondary discharge diagnoses, in addition to the primary diagnosis, for hospitalizations in all eligible children from age 16 through 24 months.
Statistical Analyses
To assess unadjusted rates of admissions per 100 000 person-years, we counted the number of hospitalizations and number of person-years according to the most recent vaccine and used these numbers to calculate the unadjusted rates. For the adjusted analyses, we used extended Cox regression (which allows for time-dependent covariates and interactions with time for variables that do not meet the proportional hazards assumption) to estimate the hazard ratios (HRs) and 95% confidence intervals (CIs). Age was the underlying time scale. In separate models, we assessed live-only vs inactivated-only, live-only vs concurrent (live and inactivated), and concurrent vs inactivated-only. We stratified by admission date for the newborn hospitalization (to control for age, seasonality, and year) and adjusted for region, urban or rural metropolitan statistical area, mother's age, low birth weight or prematurity (ICD-9 765.x for child, 644.20 and 644.21 for mother), number of previous hospitalizations prior to age 16 months (excluding hospitalization for birth), chronic conditions of the child (Supplementary Table 6 ) [8] , any previous hospitalization for NTI before age 16 months, and number of outpatient visits before age 16 months. Based on previous studies [9] , we evaluated sex as an effect modifier. Additionally, we assessed whether any other factors modified the effect of type of vaccine received on risk of hospitalization.
We assessed the risk of hospitalization until the child's first hospital admission. Children were followed from the day they turned age 16 months to hospitalization, or censorship due to disenrollment, or turning age 25 months.
We conducted sensitivity analyses that excluded vaccine-preventable diseases (VPDs) such as pneumonia (potentially vaccine-preventable pneumonias, not all pneumonias), hepatitis, pertussis, sepsis due to H. influenzae, and measles complicated by encephalitis or meningitis.
We also conducted secondary analyses for 4 groups of infections: upper respiratory infections (URI), lower respiratory infections (LRI), gastrointestinal infections, and other infections.
Similar to the Danish study [3] , we also evaluated emergency department visits for unintentional injuries (ICD-9 codes E800-E869 and E880-E929) as a control outcome using the same model as for the main analyses. We chose this event as a control outcome because it should not be causally associated with last type of vaccine received [10] .
The validity of the assumption of proportional hazards for all covariates was evaluated using Schoenfeld residuals. Violations of the proportionality assumption were identified for different variables across models. To account for these violations, we included interaction terms with time (where P < 0.05) for these terms in the models. Only vaccination status was modeled as a time-dependent variable in all the models. Joint multicollinearity was assessed using eigenvalues. Because this analysis involved only existing claims data, institutional review board review was not required.
RESULTS
We identified 687 022 infants with the code for newborn hospitalization who were enrolled within 31 days of birth and were continuously enrolled through age 15 months, after excluding those on capitated plans (n = 1917; Figure 1 ). After excluding those with immunosuppressive conditions (n = 5938) and those who received an influenza vaccine any time before age 25 months (n = 271 145), the sample included 409 939 children.
Of these, 342 659 (84%) received at least 3 doses of DTaP by age 16 months, and we could link 311 663 (91%) to their mother's information.
Of the 311 663 children included in the analyses, 51.3% were male and 45% had claims that indicated the last vaccine received prior to age 16 months was inactivated-only; for 16% the last vaccine received was live-only; 39% of the children received inactivated and live vaccines on the same day; and 44.4% had a change in their vaccination status due to receipt of additional vaccines between age 16 and 24 months ( Figure 1 ). Of those whose vaccine was live by age 16 months, 88% received MMRcontaining (ie, MMR and MMRV) vaccines (see Supplementary  Table 1 ). Among those whose last vaccination status by age 25 months was inactivated vaccine only, the majority (91.9%) had previously received MMR and/or varicella vaccine (81% received at the recommended age [ie,12-15 months] and 19% after age 15 months).
Children whose last vaccination status by age 16 months was live vaccine only differed statistically from children whose last vaccination status was inactivated-only or concurrent (live and inactivated) in that their mothers were older when they were born, they had more outpatient visits before age 16 months, were more likely to be from the northeastern United States than the south or the west, and were more likely to live in urban areas (Table 1) . Notably, there were no significant differences in last vaccination status among children with chronic conditions or those who had low birth weight or were premature.
Infectious Disease Hospital Admission Risk
The most common NTI disease hospitalizations included pneumonia (33.0%) and ear infections (17.8%; Supplementary Table 2 ). Overall, the crude rate of hospital admissions for any NTI among children aged 16 through 24 months was 1398 per 100 000 person-years ( Table 2 ). The crude rate was higher among boys than girls. The overall crude risk of hospitalization for a NTI was 1506 per 100 000 person-years among those whose last vaccine type was live-only compared with 1317 per 100 000 person-years among inactivated-only and 1599 per 100 000 person-years among concurrent receipt.
In the adjusted analyses, we found statistically significant decreases in the risk of hospitalization for NTI diseases when the last type of vaccine received included a live vaccine. In the overall Cox regression model, compared with those whose last vaccine was inactivated-only, the HR for those who received a live vaccine was 0.50 (95% CI, 0.43, 0.57; Table 2 ). This finding was also consistent for boys and for girls. Similarly, for those whose last vaccine was live-only compared with concurrent receipt of live and inactivated vaccines, the overall HR was 0.78 (95% CI, 0.67, 0.91) and was also significantly reduced among boys and girls. In the adjusted analyses, we found statistically significant reduced risks of NTI hospitalization for concurrent vaccines compared with inactivated. No factors were found to have statistically significant interaction with last vaccine type received.
Sensitivity Analyses and Control Outcome
In the secondary analyses that excluded VPDs (Table 3) , the adjusted risk of hospitalization scarcely changed from the results of the models that included VPDs. In the 4 models that evaluated NTI hospitalization risks for different categories of infections, the adjusted risk for URI and LRI was lower for those whose last vaccine type included a live vaccine compared with inactivated-only ( Table 4 ). Risk of hospitalization was lower for other viral and bacterial infections among those whose last vaccine type received was live-only compared with inactivated-only (Table 5) . We also performed the analyses to assess variation between regions, but did not find an association. (Supplementary Table 3) .
Results of the control outcome, that is, unintentional injuries, were not significantly associated with type of last vaccine received. The risk of an emergency room visit for an unintentional injury from age 16 through 24 months was not different if the type of last vaccine received was live-only compared with Live vaccines include measles-mumps-rubella-varicella, V, and MMRV. Inactivated vaccines include diphtheria-tetanus-acellular pertussis, inactivated polio virus, Haemophilus influenzae type b, pneumococcal conjugate vaccine, hepatitis B vaccine, and hepatitis A vaccine (and combined vaccines with these antigens). a Number of children by vaccine type at the end of the study.
b Adjusted for chronic conditions, low birth weight, premature, number of hospitalizations prior to age 16 months, number of outpatient visits prior to age 16 months, region, urban/rural, and mother's age. All hazard ratios are stratified by birthdate to control for age, seasonality and year, and interactions between time with previous hospitalizations and with number of outpatient visits prior to age 16 months was included to account for the violations of the proportional hazards assumption.
inactivated-only (HR, 1.16; 95% CI, 0.90, 1.48) or compared with concurrent vaccines (HR, 1.09; 95% CI, 0.83, 1.43). No difference was found when concurrent receipt was compared with inactivated vaccine.
DISCUSSION
We found a significantly lower risk of NTI hospitalization for children aged 16 through 24 months if the last type of vaccine they received was live-only compared with receipt of inactivated-only vaccines. A similar but less pronounced decreased risk was found if the type of last vaccine received was concurrent (live and inactivated) vaccines compared with inactivated-only vaccine. These findings were similar for boys and girls. The results of our secondary analyses that excluded hospitalizations for VPDs were not materially different. Thus, our study tends to support the overall findings of the Danish study [3] . Additionally, we found that the reduced risk of NTI hospitalization when the last type of vaccine was live-only was strongest for LRIs and URIs. Like the Danish study [3] , we also assessed the risk of hospitalization, including VPDs and their complications in the outcomes. Since their inclusion mixes nonspecific with specific (targeted) outcomes and could result in apparently stronger associations through the prevention of targeted outcomes, we excluded VPDs from secondary analyses. However, our results changed only minimally.
Importantly, our study extends the earlier findings of Sørup and colleagues because we evaluated the more comprehensive US childhood vaccination schedule, which includes several vaccines not included in the Danish childhood vaccination schedule. For example, the Danish study specifically evaluated MMR vs DTaP-IPV-Hib as the last vaccine received, whereas b Adjusted for chronic conditions, low birth weight, premature, number of hospitalizations prior to age 16 months, number of outpatient visits prior to age 16 months, region, urban/rural, birthdate, and mother's age. All hazard ratios are stratified by birthdate to control for age, seasonality and year, and interactions between time with number of hospitalizations prior to 16 months, with chronic conditions and with number of outpatient visits prior to age 16 months were included to account for the violations of the proportional hazards assumption.
we assessed receipt of any live vaccine (ie, MMR or varicella) and any inactivated vaccine (DTaP, Hib, IPV, PCV, HAV, and HBV). Consequently, our analyses extend support for nonspecific effects by type of vaccine rather than only by specific vaccines. Also, since children who received influenza vaccine (IIV or LAIV) may be at different risk for respiratory infections, to be consistent with the Danish study, we excluded children who ever received an influenza vaccine during the study. The 2014 Danish study [3] did not assess concurrent receipt of live and inactivated vaccines. However, in another study published in 2016, the same authors found that simultaneous administration of MMR and DTaP-IPV-Hib compared with MMR alone may increase the rate of hospital admissions related to lower respiratory tract infections [11] . Similarly, we found that receipt of live vaccine alone had a lower risk compared with inactivated alone or concurrent and that concurrent had a lower risk compared with inactivated. This suggests that the decreased risk found when a live vaccine was received alone was diluted but still present when concurrent (live and inactivated) vaccines were received compared with inactivated vaccine only.
A limitation of our study is that data on potential confounders such as the children's race and/or ethnicity and socioeconomic status were not available. Although race and/or ethnicity could not be inferred from MarketScan, socioeconomic status could Abbreviation: CI, confidence interval. a Adjusted for chronic conditions, low birth weight, premature, number of hospitalizations prior to age 16 months, number of outpatient visits prior to age 16 months, region, urban/rural, ever hospitalized previously for nontargeted infections, birthdate, and mother's age. All hazard ratios are stratified by birthdate to control for age, seasonality, and year. An interaction between time with urban/rural was included to account for the violation of the proportional hazards assumption in the gastrointestinal infections model.
be partially inferred because all the children in the database were covered by commercial health insurance plans in which the family's health insurance was provided through an employer of a family member. Also, our analysis was limited in that we were unable to conduct medical chart reviews to ensure the validity of the ICD-9 codes specified in the hospitalization inpatient claims and the CPT codes for vaccinations in the outpatient claims. Distinctly, the children included in our analyses had received at least 3 doses of DTaP, an indication that they were a vaccinated group. Consequently, we were not comparing vaccinated to unvaccinated, and therefore they differed only on the type(s) of vaccine received last. The vast majority (91.9%) of the children whose last vaccine received was inactivated by the end of the study had previously received the MMR and/ or varicella vaccines. Most received the vaccine when recommended, yet 19% received the vaccine after the recommended age of 15 months but before they received an inactivated vaccine just prior to the end of the study. Therefore, it may be that our results are affected by selection bias if the healthiest children received MMR and/or varicella vaccine by age 15 months and received the last dose of DTaP later [12] . However, if that were the case, the results should be the same for all infections. Yet, like the Danish study [3] , our results were strongest for respiratory infections. Also, there was no significant difference in the proportion of children with chronic conditions, low birth weight, or prematurity who received live or inactivated vaccines last. Moreover, in the sensitivity analyses, receipt of live vaccine last was not associated with a lower risk of unintentional injury, which implies that our results are not an effect of health-seeking bias. Last, another potential concern is misclassification bias if the 8.1% of children who did not have claims for MMR and/ or varicella vaccines actually did receive 1 or both of them, for example, through an immunization provider who did not participate in MarketScan. There is no way to know the direction of the potential misclassification with respect to the outcome.
Notably, the HRs in our analyses were less than 1, yet some of the unadjusted rates of NTI hospitalizations per 100 000 person-years were in the opposite direction. The confounding variables that impacted the adjusted results included mother's age, region, and number of outpatient visits. Inclusion of number of outpatient visits had the strongest effect on the adjusted HRs. It is not unexpected that number of prior outpatient visits would influence the risk of NTI hospitalization, but we do not know why number of outpatient visits would also be strongly associated with receiving a live vaccine only as the last vaccine.
Possible biologic mechanisms to support our findings have not been identified but could include the concept of "heterologous immunity. " That is, each person has a unique history of infections, and vaccinations and every exposure leave an imprint on the immune system that can affect future immune (innate and adaptive) responses to pathogens [13] . Additionally, studies have shown that innate immune responses have adaptive traits that have the potential to provide protection against unrelated infections, a process called "trained immunity" [14] . A review by the Institute of Medicine in 2002 concluded that "…there is strong evidence for the existence of biological mechanisms by which multiple immunizations under the current U.S. infant immunization schedule could possibly influence an individual's risk for heterologous infections" [15] .
Our study addresses a topic of current interest as evidenced by the review being conducted by the World Health Organization Strategic Advisory Group of Experts who are currently reviewing all available evidence on nonspecific vaccine effects to determine if immunization policy adjustments are needed [16] [17] [18] .
Along with other recent studies, our study raises the possibility that the order in which vaccines are administered may carry benefits in addition to the prevention of the targeted infections. But the interpretation of our results should be tempered because the extent of potential biases from confounding and selection bias is unknown. To further improve the quality of the evidence on this topic, future studies should include chart reviews to ensure the validity of the ICD codes for the outcomes of interest and to use well-validated databases or registries to ensure correct identification of vaccination status. Ideally, randomized, control trials would best control for confounding and avoid selection bias.
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